Multiplexed imaging of gene expression using the CELESTA light engine®
MERFISH (multiplex error robust fluorescence in situ hybridization) is an imaging technique that profiles cell populations based on the identification of thousands of RNA transcripts per cell.The CELESTA light engine is an ideal and widely-adopted illumination source for this application.In a recent paper published in Nature [1], Wheeler and co-workers used MERFISH imaging with a CELESTA light engine to quantify the expression of nine specific astrocyte and T-cell markers.Five of the CELESTA light engine’s seven laser lines were used in the highly multiplexed MERFISH imaging protocol.The overall objective of the research described in the paper was to characterize astrocyte populations that contribute to pathogenesis in a preclinical model of multiple sclerosis.
Reference
[1] MA Wheeler, JR Moffitt, IC Clark, EC Tjon, Z Li, SE J Zandee, CP Couturier, BR Watson, G Scalisi, S Alkwai, V Rothhammer, A Rotem, JA Heyman, S Thaploo, LM Sanmarco, J Ragoussis, DA Weitz, K Petrecca, JR Moffitt, B Becher, JP Antel, A Prat, FJ Quintana, Nature (2020) 578:593–5990
Supporting our global scientific community with lighting and fluorescence screening instrumentation designed for speed, longevity and reproducibility.
In this unprecedented time, Lumencor understands our end-user and OEM customers need high-quality data, fast. We’re working every day to supply:
Are you developing
Vaccines
Proteins including monoclonal antibodies
Drugs
Diagnostic tests
Genomic analyses and/or
Pathogen detection systems?
Lumencor is advancing global efforts in research and development with solid-state lighting specifically tailored for the instrumentation employed by those engaged in our fight against COVID-19. We understand the critical role our products serve in this fight. Lumencor remains committed to supplying our partners and customers as safely, efficiently, and expeditiously as possible. We’re here to help!
In this challenging, unprecedented time, Lumencor sends well wishes to all who are experiencing the effects of COVID-19. We are writing to confirm that Lumencor remains open and operational with safety measures in place to ensure the health and productivity of our deeply committed team of professionals.
Lumencor is ready and able to serve, advancing research and development with high-performance lighting specifically and precisely tailored to the instrumentation employed by those engaged in our fight against COVID-19. Our solid-state lighting supports the most demanding imaging and analytical testing applications including but not limited to:
diagnostic testing
drug discovery
genomic analysis
sterilization qualification and testing and
remote pathogen detection
As an industry leader, we understand the critical role our products serve in the fight against this virus and the many and varied others we seek to better understand and thereby control. Lumencor remains committed to supplying the global demand as safely, efficiently, and expeditiously as possible.
We sincerely value our relationships with you. We thank you for your patience and unwavering support of our brand during this uncertain time. We remain available through your existing Lumencor contacts so please call upon us as your needs dictate.
Lumencor’s best-in-class solid state illuminators for light microscopy and optogenetics are now better than ever. Head to booth #1519 at SfN 2018 in the San Diego Convention Center to learn how broad spectral content, brightness and precise electronic control are available for even the most demanding applications.
Here’s a preview of some of the products Lumencor will have on display at the show.
Beaverton, Oregon, (March 28, 2018) – Lumencor, Inc. investigated certain Excelitas products after their launch last year and concluded they infringe a number of Lumencor patents. The infringement pertains to light engines incorporating the high-intensity, luminescent-rod-based light sources that Lumencor calls “light pipes.” On February 2, 2018, Lumencor filed a complaint with the International Trade Commission (ITC) accusing Excelitas X-Cite Fire products of infringing Lumencor’s U.S. Patents 9,574,722, 8,493,564 and 9,395,055. These products were manufactured for Excelitas by their Canadian subsidiary Lumen Dynamics Group, Inc. On the basis of Lumencor’s complaint, the Commission instituted an investigation into violations of Section 337 of the Tariff Act by Excelitas.
Most recently, Excelitas has agreed to end importation of the accused X-Cite Fire products and also agreed not to import any light engines or light engine components which include a luminescent rod and infringe the Lumencor patents. On the basis of the agreement, both parties filed a motion for entry of a Consent Order and termination of the investigation. The Chief Administrative Law Judge of the ITC made an initial determination granting the motion on March 20. The Consent Order is expected to be issued by the Commission no later than April 19, 2018.
“Lumencor pioneered solid-state illumination for the life sciences with the development of high-intensity light pipe technology for light engines. Our technology and intellectual property are vital to the design, development and manufacture of our innovative light engines with best-in-class product performance,” said Steven M. Jaffe, Ph.D., Co-founder, President and CEO of Lumencor, Inc. “We are pleased that Excelitas decided to respect our intellectual property rights and stop the import and sale of the offending products that are accused of infringing our patents. We remain committed to enforcing our patents to preserve our exclusive rights in our patented light engine technology.”
About Lumencor, Inc.
Lumencor is leading the life sciences with light engines for bioanalysis. The company has developed innovative, powerful, pure, stable, durable and cost-effective lighting solutions designed for an array of instruments including fluorescence microscopes. Discrete outputs are available through the UV-Vis-NIR spectrum from a proprietary mix of independently controllable sources. Lumencor products provide more power than an arc lamp with the durability, stability, speed and flexibility of a solid-state solution. Lumencor products are available in OEM and off-the-shelf configurations.
Beaverton, Oregon, (January 25, 2018) – Lumencor, Inc. today announced that its counsel is commencing legal action against Excelitas Technologies Corp. and their Canadian subsidiary Lumen Dynamics Group, Inc. Lumencor has investigated the design of the newest lighting products made by Lumen Dynamics Group, Inc. and determined that the products use Lumencor’s proprietary light-pipe-based, high-intensity lighting technology. Lumencor’s patented technology is protected by U.S. Patents 9,574,722, 8,493,564 and 9,395,055, among others.
“Over the past decade, Lumencor has invested significant human and financial resources developing novel lighting innovations for the life sciences,” said Claudia B. Jaffe, Ph.D., Executive Vice President of Business Development. “We were the first to develop a light-pipe-based, high-intensity lighting solution for microscopy and related biotech equipment. Our technology and intellectual property favorably differentiate our light engines from the competition. We take great pride in, and place significant value on, our patents and the distinctions they bring to our product performance. We will protect our right to safeguard the innovation that makes our light engines unique.”
About Lumencor, Inc.
Lumencor is leading the life sciences with light engines for bioanalysis. The company has developed innovative, powerful, pure, stable, durable and cost-effective lighting solutions designed for an array of instruments including fluorescence microscopes. Discrete outputs are available through the UV-Vis-NIR spectrum from a proprietary mix of independently controllable sources. Lumencor’s products provide more power than an arc lamp with the durability, stability, speed and flexibility of a solid-state solution. Lumencor products are available in OEM and off-the-shelf configurations.
that profiles cell populations based on the identification of thousands of RNA transcripts per cell. The CELESTA light engine is an ideal and widely-adopted illumination source for this application. In a recent paper published in Nature [1], Wheeler and co-workers used MERFISH imaging with a CELESTA light engine to quantify the expression of nine specific astrocyte and T-cell markers. Five of the CELESTA light engine’s seven laser lines were used in the highly multiplexed MERFISH imaging protocol. The overall objective of the research described in the paper was to characterize astrocyte populations that contribute to pathogenesis in a preclinical model of multiple sclerosis.
